AngioDynamics, Inc.  

(Public, NASDAQ:ANGO)   Watch this stock  
Find more results for ango
16.09
0.00 (0.00%)
Oct 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 13.06 - 19.00
Open     -
Vol / Avg. 0.00/308,328.00
Mkt cap 573.64M
P/E 144.99
Div/yield     -
EPS 0.11
Shares 35.65M
Beta 0.81
Inst. own 92%
Jan 7, 2015
Q2 2015 AngioDynamics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 28, 2014
AngioDynamics Inc Annual Shareholders Meeting - 2:00PM EDT - Add to calendar
Oct 9, 2014
Q1 2015 AngioDynamics Inc Earnings Call - Webcast
Oct 9, 2014
Q1 2015 AngioDynamics Inc Earnings Release
Aug 14, 2014
AngioDynamics Inc at Canaccord Genuity Growth Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Aug '14) 2014
Net profit margin 0.54% 0.87%
Operating margin 3.71% 3.79%
EBITD margin - 13.85%
Return on average assets 0.24% 0.39%
Return on average equity 0.35% 0.58%
Employees 1,300 -
CDP Score - -

Address

14 Plaza Drive
LATHAM, NY 12110
United States - Map
+1-518-7951400 (Phone)
+1-518-7951401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AngioDynamics, Inc. designs manufacture and sell a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company�s segments include vascular segment and Oncology/Surgery. The Vascular segment, which is responsible for products targeting the venous intervention, dialysis access, thrombus management and peripheral disease markets. The Oncology/Surgery segment, which is responsible for radio frequency (RF) and microwave ablation, embolization, NanoKnife and Habib product lines. On May 21, 2012, the Company acquired Navilyst Medical. In October 2012, the Company acquired Vortex Medical Inc. In February 2013, it acquired certain assets of Microsulis Medical Ltd.

Officers and directors

Howard W. Donnelly Independent Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Joseph M. DeVivo President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Mark T. Frost Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
John J. Soto Executive Vice President, Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Matthew Kapusta Senior Vice President - Business Development
Age: 42
Bio & Compensation  - Reuters
Mark A. Stephens Senior Vice President - Administration
Age: 46
Bio & Compensation  - Reuters
Stephen A. Trowbridge Senior Vice President, General Counsel
Age: 40
Bio & Compensation  - Reuters
David F. Burgstahler Independent Director
Age: 46
Bio & Compensation  - Reuters
Jeffrey G. Gold Independent Director
Age: 66
Bio & Compensation  - Reuters
Kevin J. Gould Independent Director
Age: 60
Bio & Compensation  - Reuters